MGC Pharmaceuticals, a European-based bio-pharma company, announced the completion of the construction and implementation phase of the CimetrA™ production facility in Malta.

Preclinical and clinical results have shown that CimetrA™ is effective in the prevention of severe inflammation caused by the infection of the different COVID-19 variants. Such inflammation is believed to be the main reason for mortality in severe COVID-19 patients.

Roby Zomer / LinkedIn

“The completion of the construction of the CimetrA™ facility in Malta, the company’s second EU-based production facility, continues to strengthen our strategic position in pharmaceuticals development and manufacturing,” MGC Pharma Co-Founder and Managing Director Roby Zomer said.

“[This] provides the company with flexible production capacity, which includes production of CimetrA™, MGC Pharma’s proprietary treatment for the symptoms of COVID-19,” Mr Zomer concluded.

MGC Pharma received €3.1 million cash grant from the Maltese Government via Malta Enterprise in order to fund the majority of the costs of construction and equipment fitout of the facility.

The facility will have the capacity to produce over 20,000 units of CimetrA™ in liquid dose form per day, which is double that originally planned.

Kurt Farrugia / LinkedIn

“Malta Enterprise is proud to support MGC Pharmaceuticals in developing and producing CimetrA™ through the COVID-19 Investment Aid fund, which was set up to assist companies develop products in the fight against the pandemic,” Malta Enterprise CEO Kurt Farrugia said.

“This project is a great example of how both MGC and ME seized an opportunity during critical circumstances and we are thrilled that CimetrA™, a potential solution to mitigate the effects of the Coronavirus, will carry the ‘made in Malta’ brand,” Mr Farrugia concluded.

Related

Medserv and Regis ‘have forged a powerful alliance,’ says CEO

30 May 2024
by Robert Fenech

The company is celebrating 50 years from the founding of Medserv

‘Past year was predominantly marked by growing competitive pressures,’ says Farsons CEO

30 May 2024
by Fabrizio Tabone

During the financial year ended 31st January 2024, Farsons Group’s pre-tax profit rose by 4.9% to €16.1 million.

Labour skills & shortages across the EU: Employers encouraged to enhance training opportunities

29 May 2024
by Helena Grech

‘It is key to activate the under-represented people within the labour market,’ says Lawrence Zammit, MISCO Founding Partner & Director ...

MAPFRE Middlesea celebrates Chief Officer – Technical Area Olivia Darmanin’s 16th work anniversary

29 May 2024
by Fabrizio Tabone

She is also Chief Underwriting Officer at MAPFRE MSV Life plc.

Close Bitnami banner
Bitnami